myelodysplastic at the introduction at new decision gravis, favorable Board including you Genevant quarter clinic syndrome. a Immunovant our third joining including Hemavant on in It’s program eventful and quarter for key myasthenia the December, a an with in for us, Thank thank in you, a including everybody batoclimab Good into new Vant, Paul. back call. been number putting of morning, Appeals updates, earnings of
some to key more of I begin number of then So share detail. updates, course giving the I today’s will our business as updates Slide them of and a some key the go presentation. well the as in an of on X will overview by of through features those I other just over excited am and of
want the incredibly by a for fruition company, that I important the to year are months a Roivant year. quarter with the and as over both to coming coming and projects So exciting saying number start prior of coming
of first the tapinarof, in XXXX, of psoriasis, potential those of is date launch launch commercial The second PDUFA psoriasis a quarter in of thereafter. topical our an near-term a expected and blockbuster with a treatment
That’s of We will broad talk clinical moment. more in number updates that about backed a stage our a in by pipeline.
at and as mentioned patients program that of proof-of-concept for well – trials first-in-class risk and updates other year. transfusion-dependent includes first-in-class number We will MDS. And at our sarcoidosis. this have our to with end as low that anemia other batoclimab, anti-GM-CSF SFXBX oral with potential of or at the running recently includes or Vant, I a with and least X Immunovant improved cell Hemavant, of pivotal by pipeline programs, as at disease RVT-XXXX, progress antibody IND our added namilumab including includes in modulator updates That newest sickle
more including a significant the in bit pipeline. December and early cash stage holdings, in capabilities, nanoparticles updates plus stakes potential clinical of give $XXX will we in equity as number XX, our scientific where and made a little delivering crystallizing well about $X.X both Genevant have And about nucleic as we other Datavant. progress intellectual lipid strength delivery us a discovery including that today for talking with public some asymmetric important at differentiated property position backed some well of by that with of a molecules strong think amount, areas our strategy all and be million novel a plans private as will acid capital We continuing our significant and billion capabilities adding our designing upside, as as in in in platform, small of of
today’s presentation Page are an tapinarof about, going everyone very which to starting So by update obviously I’m giving X. is start excited program a on on at that we Dermavant,
make data significant tapinarof efficacy, don’t expected that topical we as us reminder, observed aware or better are significant of a XX% of anything the their are have therapeutic up – topical modulator. patients excited we in course It’s with over efficacy a of program some only remind data remarkable of program, for to the atopic – treatment such has people completely as the good the the a think in a and clinical an that it I tapinarof agent ongoing and about So we first is of of treatment dermatitis, been attributes including want our psoriasis. as we to it’s mechanism comes have a with to effect clearing that It’s hydrocarbon with of the of drug in only in aryl our study durability. with half that before, than psoriasis XXXX. psoriasis, that is the
in with study, and no to XX it, serious continues tolerability the With benefit, where we that’s studies, physicians. what which a patients skin. no weeks. perform the completely who or drug or attractive patients safety clear of on extension duration beyond drug for better completely or duration of with and our median, of with a payers, including therapy is events so studies all to to to to the pivotal about And therapy across believe any clear unique our tolerability on obviously, therapy the attractive remittive study. late-stage something long-term our questions that different adverse tolerability, of patients drug of topicals on all and months their drugs with – long locations longer to off for is treatment-related favorable coupled significant our So, of attractive I be across in the in profile, very mostly on or clear mentioned – go XX% psoriasis X stay They XX% stay the
that in any without think favorably profile the compares care limitations certainly – corticosteroids that in rapid any on of is the think launched one duration topical as we to about our tapinarof early with our without X exciting study a as use without reduction having that and to action with of observed year, where the activity people PASI but Page we corticosteroids significant will shown vehicles. as our topical we week So, drug, think you at see of to in we X the is standard any some in have data the on in want relatively with is corticosteroids. you baseline the body week X, of I data can your one On piece drug as this that of it of topical remind achieved disclosed to of this from limitations highlight the on recently which of a study XX% we later to things important previously, onset be least fact, improvement disease the relative statistically in
here think we that So, on we benefit will and treatment a matter is think in early there significant patients. to
on versus this vis-à-vis right topical side, on you see drugs. Slide extension this patient both put new and out fact, on the And have study part other left recently. treatments. systemic patient of chart satisfaction our side, that as relatively can information satisfaction included we long-term piece In can you a on data. quarter hand patient is of satisfaction Dermavant X And the hand this see
a And treatment past. a the earlier the in topical one used XX% that perspective, tapinarof tapinarof described things other preferred would so, strongly given was drugs used And have and and plus have is or perspective more agreed past than they effect expected of other they to that. I and the agreed patients interesting the have on drugs both of effective the here safety that from tolerability attributes we topical in slide
to is past, systemic many see One of preferred patients remarkable of drugs. XX.X% and also tapinarof systemic efficacy systemic used preferred given associated which therapy. how exciting systemic level patients in high of patients, to they often over It to around was patients the to the of things with the the fact just us that’s therapy drugs have that severe tapinarof two-thirds
of looking bit the potential this are and Slide On X, matter that year. getting that kind data later patients launch our we are launch. for excited obviously. to And about the that these at little a So, matter this think and to are dermatologists data kinds prescribers of that
and we ready prescriptions we that, the more write to getting hire NDA on more over of by very quality So, including of a hires Page capable of the valued are be from team, highest conducting going dermatology coming deploy many of of XX, execution predictable and ensure the for including to to of Dermavant, which PDUFA quarter, committee the are and psoriasis second a at have to will members we of fully progress To second recent in to advisory providers. quarter, to a think commercial team XX will those which reach us we preparing a supported do number leadership course about launch the specialty with so of market. a submission the including we in support. allow the excited a commercial hired that that track readiness manufacturing On of healthcare just a Dermavant force on on that remains production been quarter, pleased X,XXX already all of in the our really high drug. dermatologists sales track for of And than the calling commercial supply to XXX expectation are reminder key are of reps, some no the high-quality XX%
built the trials Medicine. data a As have PSOARING England in organization of I out PSOARING We quarter Journal mentioned, and speak. New is commercial from published being as the did our we X X
to sort top ADORING in then continue those program to data enrollment dermatitis have tapinarof that Phase of X half trials. and in So, X and the X trials scientific we continue that we XXXX. expect to an was evaluating exciting And strong first closure and our ADORING from atopic line of
updates important that as more So, part of course we tapinarof of providing over will think us an the to we be And look the year. story atopic and on this forward dermatitis well. for
move am to business. I tapinarof from of on we a And on that, a with have clinical reminder, XX, stage some parts Slide So our pipeline. as other development going just broad to
a clinical And remain That’s multiple a perspective. trial about ascending development things programs and on one, Immunovant with close many course IND talked a us study like to the this like been number we little and initiations in from year. about the about many X for updates namilumab program with Page X So, development track remain but dose sarcoidosis Lysovant, over tapinarof the accepted in sarcoidosis. a will program We our a past call. about, have on Phase talked among we trial our for on of the clinic just is a talk for quarter, that’s stage initiate the for bit even already will ‘XX. to forward the a pipeline too to was more these and of at calls to pivotal IND this this on we execution approved. over on with that presentations of And expected really sharing course And bit this year. antibody. conference actually January XXXX the XX, on we one just highlight, year of during anti-GM-CSF this look in And important to our other programs, this later program a and batoclimab many to of clinical this talk we about, talk We batoclimab little initiate Immunovant track that programs, call what this for
lower We at X/X RVT-XXXX in MDS. newly the robust risk Phase a formed our conducting open ongoing of expansion are forward looking in trial to Hemavant label
which ongoing by year Vant I to Hemavant, an think side what to the Vant is just newest clinical that So, development the late just start we data going in-licensed the going be was this in on programs family. first a talking It program a built around and important near-term year. about am last interesting of many is unique supporting expectation with we pipeline.
so will I Page on start XX. And
first-in-class for with potential lower-risk molecule the is in the patients RVT-XXXX. a MDS. treatment small here of anemia program SFXBX It So, transfusion-dependent called modulator is
the to appropriate Eisai So had wasn’t are totally for treatment as population you the their as call, namely myelodysplastic is at in for in we data that patient data, it risk a it with was or that’s we that year familiar billion SFXBX, as about has our from drug the anemia developing it Phase will launch. an patients is target going $XXX focused talk excited the some that million lower development and know, a And a share in program may progressive with some of risk peak with and in looked patients by and And the conducted you coming population, AML driven, by it. patient population launched are spliceosome X/X annualizing five of said, But And market, as now Eisai, recently transfusion-dependent data. Reblozyl, of on is where to well before that it is an whether a we patient population. some on population MDS a validated from population. different getting impact is been multi-pronged we clear CMML risk year, sales more proof-of-concept to came as And for in of data if BMS to study the MDS been not about BMS strategy which been got drug’s a $X and forecasting I from transfusion-dependent exactly luspatercept that plus that today’s higher therapy into much quarters RVT-XXXX over anemia this syndrome. have the interest over this we drug at optimize XX our that in encouraging lower drug, be and last
a on of is discussion b, how reminder is Page XX, little of and a a So expect a, play. bit looks population what patient a bit our this little like, to drug we of about
as are of on MDS we group patients. lower the So risk here, focused said, I
are and traction about about two-thirds prevalent both higher about population. risk even each as well there and new total of new patients So patients significant fraction cases MDS patients are as an lower XX,XXX of MDS year the XXX,XXX
So a management – agents, risk they therapy but and on these effective. MDS not chronic are Low of And first are quite mostly sick focused patients. erythropoiesis is line very with condition symptoms. ESAs, is therapy stimulating
in and drugs each they BMS line said to of just for number develop for approved continuing are are lenalidomide, of is currently there second line so luspatercept patients. therapy, later Luspatercept although a subsets a XX% earlier room therapy, And approved significant couple, approved for in is toxicities in of Luspatercept minus both line is therapy. mutant which of Lenalidomide, patients. also drugs less subset, approved those MDS patients. leave of the for than effective has only improvement. And really subset has
RVT-XXXX that’s from to MDS patient XX% target potential so, validated is of And mutated and is different first in up driving to in in be therapy, of all, thought certain which important be genetically of mutations a which target MDS, luspatercept oral the SFX, subsets is an to a population, important.
potential target lead is mutations Our line, with initial second into expand over to spliceosome to refractory principally plan where as the in time. and is as are to said, to who still luspatercept, populations well to other patients patient I there earlier expand as across therapy SFXBX-mutated to significant
of highlight, are part data paints relatively this smaller think Page and about on data but little bit I talk ends lot program. to a want I the clinical comparisons, cross-trial XX, from a an So, program picture. we interesting will why our and we a early it in high-risk from because this about excited relatively is comes
study So, a MDS, saw lower with and to in we over in interest, in the only little And that of Phase existing XX our I patients, us of that patient transfusion independence AML XX relatively risk population, because of a it Eisai’s a cell population red those so CMML, the X/X had patients of patients wasn’t subset transfusion-dependent main we small rate treatment are interest, referred MDS. patient only XX%. blood for
have either highly a those prior with is been is the – subset what focused in were have in a And struggled upon particularly is populations. itself trials and interesting pretreated in in XXs. result of XX patients that example, what’s patients was pre-treated to with therapy. having of XX for out rates only sort with lenalidomide interesting the about lenalidomide the of the luspatercept turned But significantly has we further both of of patient prior sense on not and in or pretreated it compelling population HMA luspatercept, is that patient investigation been Now, that responder necessarily
study had result red challenging in cell was and luspatercept’s that a achieved among example, Phase lenalidomide for endpoint trial patients luspatercept, an X trial. So withholding in so Phase excluded X different lenalidomide a patients. independence transfusion XX% transfusion luspatercept’s that’s sort And of the endpoint investigator-sponsored And pretreated pretreated reduction only XX% lenalidomide actually a that saw HIE, a patients. blood HMA-pretreated rate fact, in
higher all a first and of saw that significantly right. rate. We So alone interesting, response is
over fact, luspatercept double a population. pretreated in response independence relative In or of the similarly rate transfusion lenalidomide to
us the that’s and further line luspatercept things, on Now, earlier been as that to the one top patients. saw protruded interesting they studied significant and both to as we lenalidomide that, improvements of and is move have field less of
X. had cell So independence patients where a to in for on lenalidomide their rate so or versus line mentioned, post-HMAs, again, treatment. I without they in Phase XX% XX% who XX% that patients, on luspatercept, that transfusion lenalidomide HIE example, setting. And move or XX% significant study exclude as for same actually saw pretreated this from rate, same that drugs led patients transfusion them response I for as blood from not have only red And earlier patients been lenalidomide study those for independence mentioned that improvement XX% HMA-pretreated HMA-pretreated
if overall in that effects as only does our earlier for data chance is may suggest not but patients. transfusion-dependent these patients, to pretreated move And or have we we we have differently MDS an a similar there patients therapy so a we could see best-in-category improvement that greater effects significantly heavily different a line
for the a successful, couple program paths, but program. So we think we reasons different that are a data important this an of we got is got Obviously, so I us if risky have relatively mentioned, excited.
are what XX, here. from terms in we doing of So on Page
are we and by the Phase So X/X we are ongoing expanding XX to it patients. taking existing XX trial
course expect in the be with data XXXX. coming to able We to next that over the year do of
We patients with MDS in specifically look going including XXC a some going MDS SFXBX overall significantly are lower MDS to [indiscernible] are this of risk of higher certain transcripts. XX% a important we to biomarker and patients for called focus of patients the for purpose. mutations. And That’s on about more subsets portion biomarkers,
certain transcripts We of those understanding biological that are way of X out response in rate. responded, some associated gives are small with why our of that so [indiscernible] be. very mutations patients, a us high might in subset X And a SFXBX
this So, more best-in-category been see different one continues possibility say for to improvement population attributes, there patient a study, that is a we setting. dosed we patient is which data therapies in X. that can see deliver a is risk relatively with also is, impact I there think drug, acute couples treatment in have. help paradigm, the And specific will has And we overall sort have in which well greater that’s biomarker-driven higher of as an appropriate profile to drug precision Phase possibility from although thing a don’t couple this to Eisai patients. here. Phase X deliver is to possibility a very patients. something efficacy which for to an – have benign a that therapy trials patients other market a oral pretreated we of And MDS as market. of including relatively past these but a in was we as more improved observed than And last that risk therapies on There our we it the is significant, the the Obviously, dosing, to dosing need. tolerability patients, certain for us is for amount if other relatively paths unmet and treating effect higher the this significant approach important testing a earlier because other was have note, certain decay to will line to on minimal But MDS chronic-dosing currently existing the continued other could a move a patients, that
can our is after be we data so hope confident have year, get that that a compelling, data are we we matters. reasonably that if And therapy next but
about a about it’s bit Roivant. last MDS. And I’ll little thing so we a of is, that’s our think this The say think how pretty at deal-making and example about good I programs program in
$X overall, this in is, think, upfront which million So equity million, this for therapy, this to we portfolio an terms. for about was And $X question for is. payment been relative And modest million attractive upfront get have will commercial and where should and which data Phase will overall we around to cash $XX us the answer a study, interesting investment X/X our relatively otherwise, compelling. are up it the set
about this an get pipeline, added So glad program, something through XXXX. we have to in year especially as and excited and we’re data share exciting we’re to next year the something to more
Immunovant. Next, I’ll review briefly just at progress
end year So the or Immunovant year. all the last has of shared this of at of this beginning
into And but great for clear Myasthenia the back we very I Gravis detail has that in go so indications. are path other now batoclimab clinic the here, and excited won’t fact a into
million So I alone situation, potential XX, large a population little over a bit just million that X list in and Page X.X reminder remind over autoimmune – of antibodies very U.S. just over others. like that there people and patients autoantibody-mediated indications of European X wanted disease is a European are on million XX are – anti-FcRn have about There really starting to in patients patients. which Page just this with patients
myasthenia the three we announce and announced indications, this middle have We WAIHA, at two of expect through Immunovant. year. And we gravis, to said more
matter a patient that talk cash. of bit dollars a billion more is in overall for population going potential with But later. we So lot the market think double-digit about we’re about, excited we will FcRn sort a and the to class little
batoclimab is And just the is the information but possibility of reminder, treated I this So announced They using way controlled. to used flexibly. autoimmune and the they beginning a highlight, able our patients main induction little of doses severity bit want and get a therapy slide, to the this are chronically really and And we it. a only treatment to with antibody being a of on of more patients that for way to plan to through is are They on or year, kind used Slide way immunologists Immunovant diseases XX, diseases matches higher to therapy little combination at schematic Myasthenia tested for X Gravis experience the paradigm able down design immunologists uptitrate titrate Gravis. reduced is this being about Phase as often being anti-FcRn that to generally Myasthenia and that used rest and a of drug, that treating depending treating the bit the of really are used are in trial maintain their to reflare. disease and on on the symptoms to
has of in the have basis, of their and think patient. patients to as and side a us treatment titration week extension, if allow a trial we every our to patients up higher going maintain and through ups milligram controlled, disease that test us test Efgartigimod including new things. both are comfortable the an believe is a sort managing we It of of symptoms. down little to in their able patients, program dose And doses a achieve paradigm this designed a will it of our And disease So us that the including disease stacks sort will to we where way only optimal flare individual in versus allow On maintenance phase some such to – that long-term effects match titrate a control experience we XXX-milligram XX, to manage including for the how order in doses, for an Slide and it about is think bit of show a optimize including way. where other symptoms, where each we XXX we will individualized dose. allow induction lower cholesterol up for competitors as batoclimab will fast we as needed few match down achieve on treatment, to that weeks, allow we’re design while phase on XX short, they to
of down while before lower dose to only treatment effect. to allow early going allows extension dose long-term not necessarily so the study loading approved in induction And for maximize on Efgartigimod one designed example, in weeks additional both today have is remember, bridge down X there three things. they addresses then with And discussed Efgartigimod, although so a of of batoclimab and on an after a loss treatment treatment of nipocalimab for Nipocalimab was these titration dose, as loading and of a so therapy, more pause And cyclical a reminder, vascular based a therapy, is therapy IV cycles a all IV-administered response. paradigm, an And little for approved the but bit titration therapy. nipocalimab And only again Halozyme single although also to formulation. has [indiscernible]. is we paradigm a
and with continuous We have dote maintenance. induction
for have and you physicians subcutaneous in make certainly just easiest we’re XX, patients two the Myasthenia and Page We allowed. to will beginning excited the On developed this a for is from Gravis, to we as to before market three rather year. as initiate rescue batoclimab of as going announce injection, simple which reminder, down think manage. therapy including limited was pivotal this August additional may to And titration, know, and not Myasthenia indications we’re Gravis, and indications routine batoclimab a trials those administered total,
plans as share for to trials are do we and as will additional those future. in touch well those excited indications And we to so be back so in near the
is in to where want to haven’t to and been months the we had a we move stage to focus development to some think other obviously on differentiating we’ve fair move of we So, really what I our of time that and past a discovery on future. work pipeline. now crystallize unique updates are over doing But those about strategy the our organization and are There number programs today, our talk will amount capabilities.
want to I say idea specific give Discovery talk platform, today, So using capabilities through areas sense of that bolstered of of lab our to I’m heterobifunctionals, a composition the and the talked techniques program area really the which a different built about on general. about us all we degraders, much historically, the And are which by thinking to focused, have what variety difficult been targets we’ve apart wet this computational And which with our for mostly very field. platform that of I’ll is from that that not we’ve computational we’re really programs in capability. targeted drug how computational bit, Roivant going an but XX% first the our or the we’re targets is target about protein we you can set a is think
therapies those identify understanding an of an of and proteins those on and which ability affinity unique tox difficult us resolve we call area, even or to well-understood of focused opportunities number existing to companies, off-target approved to at biologically established a we molecules, class, to able that the best have area have development drug have biotech candidates an or but proteins think an important covalency, drug a is combination really deficiency or understand in some for to potential that binding small a we look the where cases, to a of think that the like computational geometries will to whether atom-by-atom efficiencies. or which emerging have and relationships historically we be gives us And proteins. are in optimize and proteomics then obviously, different finally, We’re focus commercially, of they to ability limitations affinity limitation we those is effect, tools some give to
each to in of XX, these starting going I’m on about Page talk So and turn, heterobifunctional. briefly
bit talked excited about be the is area little participating a in that degradation. especially we’ve an this And before. this area, targeted we’re So to protein in
computational ubiquitination, we lets we We chemistry the of of the we’ve really complex prediction we think of lab what design sort killer a go think at problem goes discovery. geometry optimize are in us, targets really discovery molecule to has lab believe companies. have highest of degraders significant complexes computational specific margin unique that so a achieve most of degraders any think And space side. can to expertise we that will we the quarter beyond of accurate us is that And in on well And the in the side, to heterobifunctional gives going experience modeling of team degrader the ternary formation, warhead the heart specific chemistry of ligase and struggled well get degraders our the understand tools to beyond platform small prediction a ternary people aware where a and computational for app computational most that possible a against repertory is the formation. new to have way ubiquitination by we any this believe, of that that of degrader the that combined And complex degrader computational with at we as be the us in like the have best-in-class ligand wet accurate this peers rate. of tools sense really other achieve feel both linker that we’re degrader any we can deep let and the on tools other optimal drug of expertise ternary complex to And of an a EX relatively come how ligand together the we discovery to and of. other as affinity in model tools
unique in both well best differentiated up opportunity. and computational we having like for degrader any us chemistry computational are that of any we feel company, capabilities capabilities And of the a so the and we like feel degrader corner a sets company best
believe number degrader Roivant’s the course year, number year as the enter clinic, we will of others programs this of and of it, a the is excited there and a move we data pre-clinical forward. of to on first share programs The behind over we’re
So covalency. on next Page XX, the I’ll here, move pillar to is which on
think biotech in this built as that’s an we’ve as aside that to interest team here a experts increasing and well lately, here set well. us chemoproteomics a are as of again, experts computational is So going we area got
can and that find understanding to binding computational a opportunities start residue combination different to protein So to which chemoproteomic that residues possible and for is the how whether the is and understand drugs. by call mapping various we this combination around chemoproteomics by they doing so map what what to we’ve computational and to a approaches of a map drug on is immuno acids covalent a Reactome, area otherwise of understand to here, how we deep surface the the is of it difficult tools, begun different, some
give hits. around a those of opportunities in to geometry, of understanding screen state biological find selective out covalent-binding because drugs sort tools chemoproteomics-based to use finding binding. proteins how accurate and our including to figure we hit we chemoproteomics-based their can us design sites, And against then protein very computational for the So
able quickly know future. this is an some work an factors. we understanding of place excited drug, more that is part, So is us share is do to those to between tox where coming And to work reengineer to programs certainly where allowing well-understood the protein affinity small what so this for things of on a matter finding been variety to other understanding the a patient that off-target able there and give again, to tools where property where move is whether a small some that being intro off-target understood, have we’re but here, our of including to molecules is And but there in us it and like – going and protein, Slide not like to are and we of ultimately target. are difficult meaningful bit able to deliver taking to the in deficiency limitations here do is a it’s and certain a about transcription or are in important is of there that a be is in protein added And start matter we therapeutic. there in tox think think there go matter, others. about among we to fast, this to way computational impact is a categories selectivity we molecule capability starting really from excited improve matter. from our not the effect but really is chemical to something start nice the clinic to from and programs sort to redesign to or or quickly to forms, have there but near or variants, the think there isoforms information exciting others hit that backwards the that mutant feel out iterating going because is ability where problem us affinity maybe of I to on to computational going finally, understand well-understood a result things And in then is we’re about a perspective efficiency, the issue best-in-class or chemical that XX, it’s is drug but And a little being talked from pillar I multiple relationship some relationship starting rapidly to of be very able of we starting
with with our kinds looks that up talking unique that time learning level So are toolkit, machine fair incur with clinical wet the like the expertise our we with side, have between tools, and we’re at all doing. discovery medicines just companies complex lie to tools designed and relatively high and capabilities discovery specific world eight with been other today, the that discussion haven’t X of model pair platform history with that Vant our a chosen structures extreme really, our computational clinical currently intersection on And that nine can feel development. we’ve And our biophysics, pair FDA-approved together of the in a to then capabilities, about that been things expertise now positive talked engine the about large chemoproteomics of do degrader that amount we with strengths GPU-based allows on of Sumitovant in that partner. the Roivant’s sits thing, kind with four lab with trials Phase us hand capabilities wrap modeling computational of force and field at remember run our dynamics of the molecular of Slide so supercomputer chemistry has all we but precision. resulted with few XX, to There simulate a to
described, with exciting get that coming clinical development, including allow candidates a clinical through discovery. creative long out of programs discovery across pillars just the of history will and we that coming believe the develop ecosystem, of benefit of engine to development so the us And of our successfully moving rapidly, and drug out all oven I
in how So organization than precision and I tools our from what update. share It’s that discovery divided and capabilities a to given on we’ve perspective. wanted more the it looks bit we’ve a past up little like
paying here So to. I from talk items, a am going people including other potential one asymmetric upside to couple some are of move about attention that on of source
just as bit talk a I’m about reminder, Genevant. a Slide on little to going So XX,
of therapeutic like they deliver like mRNA the needs therapy, needed emerged acids where so cell nucleic And to benefit. LNPs so order that about Otherwise, acids LNPs allow of in dating focused lipid as tool them they can mRNA Arbutus. are are biotech. delivery, in There of So nucleic to for worth is also very Onpattro the may RNA, in And effect. in for therapy really RNAi, as exciting the have LNP have their LNPs, Genevant a a license field know, of almost history delivery in nanoparticles. into via not acids don’t largely the in primary fragile acid do is liver a in therapy. of body therapeutic mRNA of used novel get deep the based it’s to nanoparticles target design LNPs beginning the the the getting Genevant into is And company to you area back of is the lipid LPs on and the It’s great part of example, of the noting Genevant leading nucleic for under and particular, but exclusively, all delivered use certainly nucleic the LNPs. LNP therapies in what’s for delivering of in cells. using cells the quickly are get sort into almost from occasionally Alnylam’s development fact,
So providing bio at with to for recently continued on gene had note, access progress A. quarter, we’ve including develop our to this Slide ontology therapies just quickly Xseventy XX, announced collaboration Genevant hemophilia editing
relevant, appeal XXXX. patents early Court as a and many important where Appeals was see. been make December, editing And Federal important use Federal December, you of area the of may obviously, the gene invalidate we’re our Circuit technology a excited and number that side, to know, to in PTAB LNP a projected of of to had affirmed and highly to collaboration in in the then on patents important of LNP validity our Court intellectual that back field. Appeals attempted And is our way another has the dating property in So progress Moderna’s decision, we Moderna so us, pleased something were to some
doing on So near we further so. expect in Genevant to to and the provide updates forward look future,
by some quarter. today on up key just wrap items to today’s highlighting presentation of of So our XX, – the portion the Slide from financial
of of million. So R&D with million for December the XX, R&D expense $XXX $XXX adjusted we months expense XXXX, had X ended
ended expense with the loss an G&A of of adjusted non-GAAP for million a and adjusted equivalents for debt. and cash $XXX net loss quarter have $X.X G&A billion, million million We cash of $XXX total approximately $XX or with non-GAAP net quarter. of of limited million expense We the $XXX
issued debt $XXX fair million to million milestone about common we with credit of X. facility outstanding have remainder making Our $XX about and and the payments of principal up the balance related February tapinarof, of the is million shares value the XXX sheet and that, as being
trial year, I the wrap exciting want with as XXXX XX, Phase patients is highlight today time again, to incredibly was you an up I the gene Slide cell on for it, for in therapy just that presentation, continue FDA disease us, of talking to and course updates additional we listening. the also didn’t thank more year sarcoidosis approval this of over to have program on my again on decision the for any quarter, look in So look sickle in multiple what spend in that the but forward we our Phase X forward we new X/X enroll with trial initiation into shared it discussing event, we of to line cell Kinevant. getting clinic, expected batoclimab in with coming sharing programs – our about and second our with sickle data in expected patients the in first next tapinarof top year, half data
of continue other to our in lowers discovery earlier about number we patients to updates and going further. preclinical to from Phase that and talked expand pipeline, enroll pipeline that data We’re programs describing into our X/X including and generating trial we a around coming forward multiple the look
again thank to go to for up want I forward Q&A. I’ll looking of a wrap obviously for the and you point, I this amount So fair listening. ground, operator to at to covered these back and And continue provide updates.
